NEW YORK (GenomeWeb News) – DiaGenic today said that it has received a NOK 7.8 million ($1.3 million) grant from the Norwegian Research Council for an Alzheimer's disease diagnostics program.
The Oslo, Norway-based firm said that the project is aimed at improving the robustness and reducing the cost of blood-based tests for Alzheimer's disease. Specifically, the project will focus on the use of microRNAs for early diagnosis of the disease.
Clinical samples will be sourced from DiaGenic's biobank and the HUNT Biosciences biobank, DiaGenic said.
"This new grant for development of blood based diagnostics for early Alzheimer's disease represents an important financial contribution," DiaGenic CEO Henrik Lund said in a statement.
Two months ago, DiaGenic inked a deal with GE Healthcare to develop a blood-based test using DiaGenic's gene expression profiling tools for the early detection of a disorder associated with Alzheimer's disease.